tiprankstipranks
Trending News
More News >

Thiogenesis Expands European Reach with New Consultancy Agreement

Story Highlights
Thiogenesis Expands European Reach with New Consultancy Agreement

Confident Investing Starts Here:

An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.

Thiogenesis Therapeutics Corp. has entered into a consulting and investor relations agreement with Bull Markets Media GmbH to expand its shareholder base and network in Europe. The agreement involves a consultancy fee and stock options, with the possibility of annual renewal for two additional years, subject to TSX Venture Exchange approval. This strategic move is expected to enhance Thiogenesis’s market presence in Europe, potentially impacting its operations and stakeholder engagement positively.

More about Thiogenesis Therapeutics Corp

Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing sulfur-containing prodrugs that become active only upon metabolism. These prodrugs aim to treat serious pediatric diseases with unmet medical needs, leveraging streamlined regulatory pathways to enhance drug bioavailability and reduce side effects. Target indications include MELAS, Leigh syndrome, Rett syndrome, and pediatric MASH.

YTD Price Performance: 10.0%

Average Trading Volume: 20,167

Technical Sentiment Consensus Rating: Sell

Current Market Cap: C$29.08M

Learn more about TTI stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App